PUBLISHER: 360iResearch | PRODUCT CODE: 1496751
PUBLISHER: 360iResearch | PRODUCT CODE: 1496751
[189 Pages Report] The Biopharmaceutical Excipients Market size was estimated at USD 2.29 billion in 2023 and expected to reach USD 2.53 billion in 2024, at a CAGR 10.75% to reach USD 4.70 billion by 2030.
Biopharmaceutical excipients are substances other than therapeutic molecules that are included in a biopharmaceutical formulation to aid in the production, stability, usability, and delivery of the drug. Biopharmaceutical excipients play a pivotal role in drug formulation. Their applications span diverse categories, such as binders, fillers, diluents, disintegrants, and stabilizers. Rising demand for advanced and functional biopharmaceutical drug formulations and increasing need for large-molecule development are driving the adoption of biopharmaceutical excipients. In addition, rising investment in drug development is boosting the utilization of biopharmaceutical excipients. However, the compatibility issues of biopharmaceutical formulations with active pharmaceutical ingredients pose considerable challenges. Furthermore, the continuous development of biologics and biosimilars leads to an increased need for compatible excipients. Technological advancements in extended-release formulations and the exploration of alternative routes of administration provide significant potential for market expansion.
KEY MARKET STATISTICS | |
---|---|
Base Year [2023] | USD 2.29 billion |
Estimated Year [2024] | USD 2.53 billion |
Forecast Year [2030] | USD 4.70 billion |
CAGR (%) | 10.75% |
Regional Insights
In the Americas, the United States stands as a dominant player within the biopharmaceutical excipients market due to a robust pharmaceutical industry, significant investment in R&D, and a steady number of FDA approvals. Canada contributes to regional demand, and both countries exhibit a high interest in novel, multifunctional excipients that enhance drug delivery and stability. European Union (EU) countries possess a well-established pharmaceutical sector with stringent regulatory standards. Consumer need is driven by the production of biosimilars and biologics that demand high-quality ingredients. Ongoing investments by the European Union in research and innovation programs indicate a continued commitment to excipient development, including potential patent applications that aim at improving the performance and safety of biopharmaceuticals. In the APAC region, the focus is on the innovation and development of new excipients and a strong government push for upgrading the pharmaceutical industry. In India, a hub for generic drug production, the excipient demand aligns with cost efficiency and compliance with international standards. Across the Asia Pacific, diverse customer needs steer the demand for specific excipients, which are expected to fuel market growth.
Market Insights
The market dynamics represent an ever-changing landscape of the Biopharmaceutical Excipients Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.
FPNV Positioning Matrix
The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Biopharmaceutical Excipients Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Biopharmaceutical Excipients Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Recent Developments
Roquette launches three moisture-protecting ingredients for nutraceuticals
Roquette has expanded its portfolio of biopharmaceutical excipients with the introduction of three new grades specifically tailored to enhance the stability of moisture-sensitive active pharmaceutical and nutraceutical ingredients. The newly unveiled grades are the partially pregelatinized starch Lycatab CT-LM and two microcrystalline cellulose variants, Microcel 103 SD and Microcel 113 SD, which provide an unparalleled combination of stabilizing properties and moisture protection. [Published On: 2023-10-26]
Croda Pharma Breaks Ground on Excipients Manufacturing Facility
Croda Pharma has initiated the construction of an advanced manufacturing facility in Lamar, Pennsylvania, focused on producing advanced biopharmaceutical excipients crucial for cutting-edge drug delivery systems. With a footprint of 23,680 square feet, this facility is poised to significantly bolster the production of ingredients vital for mRNA vaccines, gene therapies, and innovative cancer treatments, fulfilling an emerging demand in therapeutic modalities. [Published On: 2023-06-14]
Strategy Analysis & Recommendation
The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Biopharmaceutical Excipients Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.
Key Company Profiles
The report delves into recent significant developments in the Biopharmaceutical Excipients Market, highlighting leading vendors and their innovative profiles. These include ABITEC Corporation, Actylis, Ashland Global Holdings Inc., BASF SE, Clariant International Ltd., Colorcon, Inc., Croda International PLC, DFE Pharma GmbH & Co KG, Eastman Chemical Company, Evonik Industries AG, Fuji Chemical Industries Co., Ltd., IMCD N.V., Innophos Holdings, Inc., J. Rettenmaier & Sohne GmbH + Co KG, Meggle Group GmbH, Merck KGaA, Roquette Freres S.A., Sigachi Industries Limited, Spectrum Laboratory Products, Inc., SPI Pharma, Inc., The Dow Chemical Company, The Lubrizol Corporation, VWR International, LLC by Avantor, and Wacker Chemie AG.
Market Segmentation & Coverage